Logo image
Back
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Journal article   Open access   Peer reviewed

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

Michael Crump, Sattva S Neelapu, Umar Farooq, Eric Van Den Neste, John Kuruvilla, Jason Westin, Brian K Link, Annette Hay, James R Cerhan, Liting Zhu, …
Blood, Vol.130(16), pp.1800-1808
10/19/2017
DOI: 10.1182/blood-2017-03-769620
PMCID: PMC5649550
PMID: 28774879
url
https://doi.org/10.1182/blood-2017-03-769620View
Published (Version of record) Open Access

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Although 5-year survival rates in the first-line setting range from 60% to 70%, up to 50% of patients become refractory to or relapse after treatment. Published analyses of large-scale outcome data from patients with refractory DLBCL are limited. SCHOLAR-1, an international, multicohort retrospective non-Hodgkin lymphoma research study, retrospectively evaluated outcomes in patients with refractory DLBCL which, for this study, was defined as progressive disease or stable disease as best response at any point during chemotherapy (>4 cycles of first-line or 2 cycles of later-line therapy) or relapsed at ≤12 months from autologous stem cell transplantation. SCHOLAR-1 pooled data from 2 phase 3 clinical trials (Lymphoma Academic Research Organization-CORAL and Canadian Cancer Trials Group LY.12) and 2 observational cohorts (MD Anderson Cancer Center and University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence). Response rates and overall survival were estimated from the time of initiation of salvage therapy for refractory disease. Among 861 patients, 636 were included on the basis of refractory disease inclusion criteria. For patients with refractory DLBCL, the objective response rate was 26% (complete response rate, 7%) to the next line of therapy, and the median overall survival was 6.3 months. Twenty percent of patients were alive at 2 years. Outcomes were consistently poor across patient subgroups and study cohorts. SCHOLAR-1 is the largest patient-level pooled retrospective analysis to characterize response rates and survival for a population of patients with refractory DLBCL.
 Adult Aged Aged, 80 and over Drug Resistance, Neoplasm Female Humans International Cooperation Lymphoma, Large B-Cell, Diffuse - epidemiology Lymphoma, Large B-Cell, Diffuse - therapy Male Middle Aged Multicenter Studies as Topic - statistics & numerical data Observational Studies as Topic - statistics & numerical data Randomized Controlled Trials as Topic - statistics & numerical data Retrospective Studies Salvage Therapy Treatment Outcome Young Adult

Details

Metrics

32 Record Views
1394 Times Cited - Web of Science
Logo image